Recently, a Phase 3 trial, focusing on the efficacy of immunotherapy plus antiangiogenic therapy and chemotherapy for NSCLC patients who had progressed disease after EGFR‐TKI treatment, showed that mPFS was significantly longer in the sintilimab plus IBI305 plus chemotherapy group compared with chemotherapy alone (6.9 months [95% CI: 6.0–9.3] versus 4.3 months [95% CI: 4.1–5.4]; HR: 0.46 [95% CI: 0.34–0.64], p < 0.0001).21 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.